Editorial: Expert opinions in genitourinary oncology.
作者信息
Lagos Galina G, El-Deiry Wafik S, Cheng Liang
机构信息
Hematology-Oncology Division, Department of Medicine, Rhode Island Hospital and Brown University, Providence, RI, United States.
Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, United States.
出版信息
Front Oncol. 2024 Jan 24;13:1360223. doi: 10.3389/fonc.2023.1360223. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Expert opinions in genitourinary oncology.
Front Oncol. 2024 Jan 24;13:1360223. doi: 10.3389/fonc.2023.1360223. eCollection 2023.
2
Long non-coding RNAs in genitourinary malignancies: a whole new world.
Nat Rev Urol. 2019 Aug;16(8):484-504. doi: 10.1038/s41585-019-0195-1.
3
The Microbiome and Genitourinary Cancer: A Collaborative Review.
Eur Urol. 2019 Apr;75(4):637-646. doi: 10.1016/j.eururo.2018.12.043. Epub 2019 Jan 15.
4
Factors associated with suicide in patients with genitourinary malignancies.
Cancer. 2015 Jun 1;121(11):1864-72. doi: 10.1002/cncr.29274. Epub 2015 Feb 17.
5
Editorial: Methods in genitourinary oncology.
Front Oncol. 2023 Aug 24;13:1274264. doi: 10.3389/fonc.2023.1274264. eCollection 2023.
6
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.
Future Oncol. 2016 Sep;12(17):1971-4. doi: 10.2217/fon-2016-0166. Epub 2016 Jun 17.
7
The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
BMC Urol. 2022 Nov 30;22(1):196. doi: 10.1186/s12894-022-01141-1.
8
Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management.
Eur Urol Focus. 2021 May;7(3):513-521. doi: 10.1016/j.euf.2021.06.002. Epub 2021 Jun 22.
9
Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America.
J Urol. 2005 Dec;174(6):2330-3. doi: 10.1097/01.ju.0000181828.95803.94.
10
Editorial: The mechanism of tumor evolution and microenvironmental changes of genitourinary oncology in clinical diagnosis and treatment.
Front Oncol. 2023 Aug 29;13:1272984. doi: 10.3389/fonc.2023.1272984. eCollection 2023.
引用本文的文献
1
CT-Based radiomics and deep learning for the preoperative prediction of peritoneal metastasis in ovarian cancers.
Abdom Radiol (NY). 2025 Aug 13. doi: 10.1007/s00261-025-05162-w.
本文引用的文献
1
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3.
2
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2.
3
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4.
4
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12.
5
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23.
6
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16.
7
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
8
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
9
Will the Use of Biomarkers Improve Bladder Cancer Radiotherapy Delivery?
Clin Oncol (R Coll Radiol). 2021 Jun;33(6):e264-e273. doi: 10.1016/j.clon.2021.03.017. Epub 2021 Apr 16.
10
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
PLoS One. 2020 May 26;15(5):e0233260. doi: 10.1371/journal.pone.0233260. eCollection 2020.
Zotero 插件